MONTREAL, CANADA--(Marketwire - December 13, 2007) - ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that it has received an order from a European client for its recently released preclinical optical molecular imaging system, the Optix® MX2. The unit is expected to be shipped before the end of the year. This represents the first Optix unit sold in Europe by ART under its new commercial strategy.
